Interview with Christian Schilling, CEO, Boehringer Ingelheim Austria
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Company information:
BBMRI Austria is the Austrian National Node of the European biobanking research infrastructure BBMRI-ERIC.
BBMRI Austria links Austrian universities and biobanks with the goal to establish a national biobanking research infrastructure for accelerating biomedical research.
Address: Neue Stiftingtalstrasse 2/B/6, A-8010 Graz, Austria
Website: http://bbmri.at/
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed…
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
Just like other European countries, Austria is in the search for meaningful savings in healthcare. Austria’s increasingly price sensitive pharma market is seeing the rise of generic medicines gaining market…
Whereas most General Managers are exposed to different countries during their professional career, you have chosen to dedicate yours to the Austrian market. What is it in this country so…
You have been General Secretary of PHARMIG since 2004 and have witnessed the market’s development over the past 8 years. What have been the most important changes since you started…
See our Cookie Privacy Policy Here
